Renowned plant-based physician Dr. Michael Greger has released a new book on the risks, benefits, and alternatives to Ozempic ...

Semaglutide, the glucagon-like peptide 1 receptor agonist from Novo Nordisk A/S, which has seemingly improved every disease it’s been tested on, was a focus at Kidney Week 2024, where researchers ...

Findings from a meta-analysis comparing surgical and pharmacologic weight loss interventions also highlighted the clinical ...

It's no secret that doctors are helping many people lose weight by prescribing GLP-1 medications like Ozempic, Wegovy, ...

In this case report, Gad and colleagues performed corneal confocal microscopy to assess for evidence of nerve regeneration ...

This analysis from the FLOW trial showed that once-weekly subcutaneous semaglutide 1.0 mg significantly lowered the risk of ...

Although the FDA approved semaglutide for weight loss in 2021, this medication isalso used in treating type 2 diabetes and in ...

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with ...

Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...